UnitedHealth Group (NYSE:UNH) had its price target upped by investment analysts at Morgan Stanley from $275.00 to $277.00 in a research note issued to investors on Wednesday. The brokerage presently has an “overweight” rating on the healthcare conglomerate’s stock. Morgan Stanley’s price target indicates a potential upside of 16.12% from the company’s current price.
Several other research firms also recently commented on UNH. Zacks Investment Research upgraded UnitedHealth Group from a “hold” rating to a “buy” rating and set a $267.00 price objective on the stock in a report on Saturday, January 20th. JPMorgan Chase boosted their price target on UnitedHealth Group to $266.00 and gave the company an “overweight” rating in a report on Wednesday. Argus boosted their price target on UnitedHealth Group to $270.00 and gave the company a “buy” rating in a report on Thursday, January 18th. Deutsche Bank boosted their price target on UnitedHealth Group to $260.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Finally, Citigroup boosted their price target on UnitedHealth Group from $235.00 to $268.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Three research analysts have rated the stock with a hold rating and twenty-six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $247.06.
UNH opened at $238.55 on Wednesday. The stock has a market capitalization of $222,872.13, a PE ratio of 23.69, a P/E/G ratio of 1.34 and a beta of 0.77. The company has a current ratio of 0.73, a quick ratio of 0.73 and a debt-to-equity ratio of 0.58. UnitedHealth Group has a 12 month low of $166.65 and a 12 month high of $250.79.
UnitedHealth Group (NYSE:UNH) last released its quarterly earnings data on Tuesday, April 17th. The healthcare conglomerate reported $3.04 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.91 by $0.13. The firm had revenue of $55.19 billion for the quarter, compared to the consensus estimate of $54.90 billion. UnitedHealth Group had a return on equity of 21.29% and a net margin of 5.25%. The company’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.37 earnings per share. analysts predict that UnitedHealth Group will post 12.52 earnings per share for the current year.
In other UnitedHealth Group news, insider Larry C. Renfro sold 22,184 shares of the company’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $228.94, for a total transaction of $5,078,804.96. Following the transaction, the insider now owns 173,229 shares in the company, valued at approximately $39,659,047.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William C. Ballard, Jr. sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $246.38, for a total value of $2,463,800.00. Following the transaction, the director now owns 76,637 shares in the company, valued at approximately $18,881,824.06. The disclosure for this sale can be found here. Insiders have sold a total of 77,015 shares of company stock worth $17,879,199 in the last quarter. Company insiders own 0.89% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Exane Derivatives boosted its position in shares of UnitedHealth Group by 15,333.3% in the 4th quarter. Exane Derivatives now owns 463 shares of the healthcare conglomerate’s stock worth $102,000 after purchasing an additional 460 shares in the last quarter. Aevitas Wealth Management Inc. bought a new stake in shares of UnitedHealth Group in the 4th quarter worth approximately $102,000. Pathstone Family Office LLC bought a new stake in shares of UnitedHealth Group in the 4th quarter worth approximately $129,000. Trustcore Financial Services LLC bought a new stake in shares of UnitedHealth Group in the 4th quarter worth approximately $133,000. Finally, Intellectus Partners LLC boosted its position in shares of UnitedHealth Group by 18.2% in the 2nd quarter. Intellectus Partners LLC now owns 818 shares of the healthcare conglomerate’s stock worth $152,000 after purchasing an additional 126 shares in the last quarter. 86.78% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/18/unitedhealth-group-unh-price-target-raised-to-277-00.html.
About UnitedHealth Group
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.